SCHEMBL4895426

SCHEMBL4895426

CC(C)Oc1ccc2c(c1)Cc1cc(OC(C)C)ccc1-2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
PDK2 Q15119 1/20 0.44
KMT2A Q03164 2/20 0.43
MAPT P10636 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
CES2 O00748 1/20 0.42
PARP10 Q53GL7 1/20 0.41
METAP1 P53582 1/20 0.41
BRD4 O60885 1/20 0.41
BRPF1 P55201 1/20 0.41
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ALDH1A3 P47895 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15395721 0.91 MAPT (0.50) ALDH1A1PDK2MAPTNPC1RAB9A
SCHEMBL4897533 0.88 CES2 (0.45) ALDH1A1PDK2KMT2AMAPTCES2
SCHEMBL14342994 0.84 HTR2C (0.44) ALDH1A1KMT2AMAPTNPC1RAB9A
SCHEMBL30218157 0.83 METAP1 (0.46) ALDH1A1PDK2KMT2ACES2PARP10
SCHEMBL6766300 0.83 MAOA (0.56) ALDH1A1PDK2KMT2AMAPTNPC1
SCHEMBL4896222 0.81 HTR2A (0.40) ALDH1A1KMT2AMAPTNPC1RAB9A
SCHEMBL21732515 0.81 ALDH1A1 (0.46) ALDH1A1KMT2ANPC1RAB9APARP10
SCHEMBL31638161 0.78 CES2 (0.54) ALDH1A1KMT2ACES2PARP10METAP1
SCHEMBL16473527 0.78 TSHR (0.50) ALDH1A1KMT2ANPC1RAB9AALOX15
SCHEMBL14075675 0.78 SMN1; SMN2 (0.46) ALDH1A1MAPTNPC1RAB9AALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101107260-B Transition metal complex, method for producing the same, substituted fluorene compound, method for producing the substituted fluorene compound, catalyst component for olefin polymerization, catalyst for olefin polymerization, and method for producing olefin polymer SUMITOMO CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-8084559-B2 Ethylene-vinylcyclohexane copolymers SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-27 US disclosed
US-20080161514-A1 Transition Metal Complex, Process For Producing Said Transition Metal Complex, Substituent-Carrying Fluorene Compound, Process For Producing Said Fluorene Compound, Catalyst Component For Olefin Polymerization, Catalyst For Olefin Polymerization, and Process For Producing Olefin Polymer SUMITOMO CHEMICAL COMPANY, LIMTIED (JP) 2008-07-03 US disclosed
CN-101107260-A Transition metal complex, method for producing the same, substituted fluorene compound, method for producing the substituted fluorene compound, catalyst component for olefin polymerization, catalyst for olefin polymerization, and method for producing olefin polymer SUMITOMO CHEMICAL CO (JP) 2008-01-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161514-A1 Transition Metal Complex, Process For Producing Said Transition Metal Complex, Substituent-Carrying Fluorene Compound, Process For Producing Said Fluorene Compound, Catalyst Component For Olefin Polymerization, Catalyst For Olefin Polymerization, and Process For Producing Olefin Polymer AOC2, ACSL1, ACSL3 ALDH1A1 1292/4885PDK2 673/4885KMT2A 2321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.